Shareholders meeting

July 9, 2026 BSE Limited The National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Exchange Plaza, Street, Mumbai – 400 001 Bandra Kurla Complex Bandra (E), Mumbai – 400 001 Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ Dear Sir/Madam, Sub: Notice of the 42nd Annual General Meeting Please find enclosed the Notice convening the 42nd Annual General Meeting ("AGM") of the Company to be held on August 4, 2026, at 10:00 a.m. (IST) through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM"). The Notice of AGM is also available on the Company’s website and can be accessed at the following link: Notice of the 42nd Annual General Meeting This is for your information and records. Thanking you Yours Sincerely, For Neuland Laboratories Limited Sarada Bhamidipati Company Secretary Encl: As above Notice Integrated Annual Report 2025-26 NEULAND LABORATORIES LIMITED (CIN: L85195TG1984PLC004393) Registered Office: 11th Floor (5th Office Level), Phoenix IVY Building, Plot No.573A-III, Road No. 82, Jubilee Hills, Hyderabad- 500033 E-mail: ir@neulandlabs.com, website: www.neulandlabs.com, Tel: +91-40-6761 1600 NOTICE NOTICE is hereby given that the Forty Second Annual for payment of a sum not exceeding one percent per General Meeting of the Members of Neuland Laboratories annum of the net profits of the Company calculated Limited will be held on 4th August, 2026 at 10.00 A.M. (IST) in accordance with the provisions of Section 198 of through Video Conferencing (“VC”) / Other Audio-Visual the Act, in addition to the sitting fees for attending the Means (“OAVM”) to transact the following business: meeting(s) of the Board of Directors of the Company or any Committee thereof be paid to the Non- ORDINARY BUSINESS Executive Directors of the Company in such amounts or proportions and in such manner as may be decided 1. To receive, consider and adopt: by the Nomination and Remuneration Committee / Board of Directors and such payments shall be made in (a) the Audited Financial Statements of the Company respect of the profits of the Company for each year, for for the financial year ended March 31, 2026, a period of five years, commencing from the financial together with the reports of the Board of Directors year 2026-27.” and the Auditors’ thereon; and 5. Appointment of Dr. Mauricio Futran (DIN: 11699767) (b) the Audited Consolidated Financial Statements as Non-Executive Non-Independent Director of of the Company for the financial year ended the Company March 31, 2026, together with the report of the Auditors thereon. Toconsiderand,ifthoughtfit,topassthefollowing resolutionasan Ordinary Resolution: 2. T o declare final dividend of ` 34/- (340 %) per equity share of a face value of ` 10/- each, for the financial “RESOLVED THAT pursuant to Section 152 of the year 2025-26 as recommended by the Board. Companies Act, 2013 (‘the Act’) and other applicable provisions, if any, of the Act and the relevant rules made 3. T o appoint a Director in place of Dr. Davuluri Rama thereunder (including any statutory modification(s) or Mohan Rao (DIN: 00107737), who retires by rotation amendment(s) thereto or reenactment(s) thereof for and being eligible, offers himself for re-appointment. the time being in force), Regulation 17 of the Securities and Exchange Board of India (Listing Obligations and SPECIAL BUSINESS Disclosure Requirements) Regulations, 2015, as 4. P ayment of Commission to the Non-executive amended from time to time, in accordance with the Directors of the Company Articles of Association of the Company and based on the recommendation of the Nomination & Remuneration Toconsiderand,ifthoughtfit,topassthefollowing Committee and the approval of the Board of Directors, resolutionasanOrdinary Resolution: Dr. Mauricio Futran (DIN: 11699767), who was appointed as an Additional Director of the Company in “RESOLVED THAT pursuant to the provisions of the category of Non-Executive Non-Independent by Sections 197 and other applicable provisions, if any, the Board of Directors in terms of Section 161(1) of the of the Companies Act, 2013 (Act) and the Rules made Act and in respect of whom the Company has received thereunder, (including any statutory modification(s) or a notice in writing under Section 160 of the Act, from re-enactment thereof), and Securities and Exchange a Member, proposing his candidature for the office of Board of India (Listing Obligations and Disclosure Director, be and is hereby appointed as Non-Executive Requirements) Regulations, 2015, as amended, Non-Independent Director of the Company, liable to consent of the Company be and is hereby accorded retire by rotation, with effect from May 12, 2026. Neuland Laboratories Limited “RESOLVED FURTHER THAT the Board be and is All the travel (Business class), boarding and stay in hereby authorized to do all such acts, deeds, matters India would be organized and paid for by the Company. and things as it considers necessary or expedient for Any other incidental expenses incurred would be the purpose of giving effect to this Resolution.” reimbursed based on actual expenses. 6. Payment of professional fees to Dr. Mauricio Futran “RESOLVED FURTHER THAT the Board be and is hereby (DIN: 11699767) Non-Executive Non-Independent authorized to revise, modify, amend or rectify the Director of the Company terms and conditions of aforesaid letter of agreement including any revision of payment of professional fees  Toconsiderand,ifthoughtfit,topassthefollowing as it may deem fit, in accordance with the overall resolutionasan Ordinary Resolution: limits specified under the Act and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, “RESOLVED THAT pursuant to Section 188 of the 2015, as may be applicable, and to do all such acts, Companies Act, 2013 (‘the Act’) and other applicable deeds and things as may be considered necessary, provisions, if any, of the Act and the relevant rules made desirable or expedient to give effect to this resolution.” thereunder (including any statutory modification(s) or amendment(s) thereto or reenactment(s) thereof 7. Ratification of remuneration of Cost Auditors for the time being in force), and Regulation 23 and other applicable provisions of the Securities Toconsiderand,ifthoughtfit,topassthefollowing and Exchange Board of India (Listing Obligations resolutionasanOrdinary Resolution: and Disclosure Requirements) Regulations, 2015, (including any statutory modification(s), clarification(s), “RESOLVED THAT pursuant to the provisions of Section substitution(s) or re-enactment(s) thereof for the time 148 and other applicable provisions, if any, of the being in force), and based on the recommendation of Companies Act, 2013 and the Companies (Audit and the Audit Committee and the approval of the Board of Auditors) Rules, 2014, the members of the Company Directors, the Company hereby accords its consent to be and hereby ratify the remuneration of ` 4,00,000 Dr. Mauricio Futran (DIN: 11699767), Director of the (Rupees Four lakhs only) and taxes as applicable plus Company, to hold office or place of profit for a period out-of-pocket expenses payable to M/s. Nageswara of five years with effect from May 12, 2026, upon the Rao & Co., Cost Accountants, (Registration No. terms and conditions set out in the letter of agreement, 000332), Hyderabad, Cost Auditors appointed by the subject to the professional fees mentioned below: Board of Directors of the Company to audit the cost records maintained by the Company for the financial a. U SD 10,000 per year – Scientific Advisory year ending March 31, 2027. Board role RESOLVED FURTHER THAT the Board of Directors be b. U SD 21,000 per year – retainer for advisory and is hereby authorised to do all such acts, deeds services (covering 60 hours per year) and things as may be necessary to give effect to this Resolution.” c. USD 350 per hour – for hours beyond 60 hours per [Showing first 8,000 characters — download PDF for full document]